CRSP CRISPR Therapeutics AG gains 21% May 31, 2018

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.http://www.priceseries.com/trade/CRSP-CRISPR-Therapeutics-AG-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018051020180531.html